The preclinical profile of asenapine: Clinical relevance for the treatment of schizophrenia and bipolar mania

Expert Opinion on Drug Discovery

Volumn 8, Issue 1, 2013, Pages 93-103

  Tarazi, Frank I ^a   Neill, Jo C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Animal models; Asenapine; Bipolar mania; Chronic treatment; Cognition; Receptor pharmacology; Schizophrenia

Indexed keywords

ADRENERGIC RECEPTOR; AMPHETAMINE; APOMORPHINE; ASENAPINE; CLOZAPINE; DOPAMINE RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; SEROTONIN RECEPTOR;

AVOIDANCE BEHAVIOR; BIPOLAR MANIA; BRAIN DAMAGE; CATALEPSY; CHRONIC STRESS; COGNITIVE DEFECT; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; STARTLE REFLEX; VENTROMEDIAL PREFRONTAL CORTEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG EVALUATION, PRECLINICAL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA;

EID: 84871552202     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.738193     Document Type: Review

References (94)

1. Product Information Saphris-(asenapine) sublingual tablets. Initial US approval: 2009
2. Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today 2009;45:865-76
3. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 2012;13:1911-22
4. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55
5. Peeters PAM, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics: influence of hepatic and renal impairment [Abst NR4-081]. 161st Amer Psychiatric Assoc; 3-8 May; Washington DC; 2008
6. Chapel S, Hutmatcher M, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. J Clin Psychopharmacol 2009;49:1297-308
7. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73
8. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72
9. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-85
10. Ghanbari R, El Mansari M, Shahid M, et al. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha2 and D2 receptors in the rat brain. Eur Neuropsychopharmacol 2009;19:177-87
11. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-81
12. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-62
13. Ichikawa J, Dai J, O'Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39
14. Assié MB, Ravailhe V, Faucillon V, et al. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005;315:265-72
15. Huang M, Li Z, Dai J, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008;33:2934-45
16. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-84
17. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 2005;27(Suppl A):S25-37
18. Millan MJ, Dekeyne A, Gobert A. Serotonin 5-HT2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998;37:953-5
19. Owen JC, Whitton PS. Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha2 and 5-HT1A receptors. Neurosci Lett 2003;348:171-4
20. Devoto P, Flore G, Pira L, et al. Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem 2004;88:1003-9
21. Fra°nberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29
22. Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm 1993;91:197-221
23. Marcus MM, Nomikos GG, Svensson TH. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol 1996;6:29-38
24. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-41
25. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;12(1-2):21-36
26. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77
27. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York; 2005. p. 461-500
28. Tarazi FI, Moran-Gates T, Wong EH, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008;198:103-11
29. Tarazi FI, Yeghiayan SK, Baldessarini RJ, et al. Long-term effects of S(+)N-npropylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology 1997;17:186-96
30. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711-17
31. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3-16
32. Fleming K, Potkin SG, Binneman B, et al. Asenapine improves cognitive function in acute schizophrenia: A placebo-and risperidone-controlled trial [Abst NR513]. 160th Amer Psychiatric Assoc; 19-24 May; San Diego, CA; 2007
33. Marin C, Parashos SA, Kapitzoglou-Logothetis V, et al. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 1993;45:195-200
34. Parashos SA, Marin C, Barone P, et al. Effect of chronic D1 and/or D2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl) 1990;102:411-13
35. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997;280:561-9
36. Lidow MS, Goldman-Rakic PS. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997;283:939-46
37. Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 1992;31:560-70
38. Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010;24:341-8
39. Kuoppamaki M, Seppala T, Syvalahti E, et al. Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 1993;264:1262-7
40. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002;161:263-70
41. Diaz-Mataix L, Scorza MC, Bortolozzi A, et al. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005;25:10831-43
42. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
43. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-15
44. Burnet PW, Chen CP, McGowan S, et al. The effects of clozapine and haloperidol on serotonin-1A,-2A and-2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996;73:531-40
45. Rauser L, Savage JE, Meltzer HY, et al. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor. J Pharmacol Exp Ther 2001;299:83-9
46. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004;26:1936-46
47. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500
48. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-20
49. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 2000;31:302-12
50. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 2001;41:237-60
51. Choi YK, Wong EH, Henry B, et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-10
52. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1145-58
53. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004;174:25-31
54. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008;107:1188-95
55. Salmi P, Samuelsson J, Ahlenius S. A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Methods 1994;32:155-9
56. Wadenberg ML, Hicks PB. The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23:851-62
57. Castagné V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 2009;57:381-418
58. Marston HM, Young JW, Martin FD, et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 2009;206:699-714
59. Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 2010;4:349-71
60. Geyer MA, Krebs-Thomson K, Braff DL, et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54
61. Auclair AL, Kleven MS, Besnard J, et al. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 2006;31:1900-9
62. Ahlenius S, Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre-and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 1986;24:1409-15
63. Wadenberg ML, Soliman A, VanderSpek SC, et al. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-41
64. Klein D. Depression and anhedonia. In: Clark C, Fawcett J, editors. Anhedonia and affect deficit states. PMA Publishing; New York, NY: 1984
65. Papp M, Moryl E, Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996;296:129-36
66. Papp M, Panconi E, Gruca P. Effects of the novel antidepressant milnacipran in a chronic mild stress model of depression. Drug Develop Res 2004;61:101-6
67. Papp M, Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 2000;14:46-52
68. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134:319-29
69. Marston HM, Martin FD, Papp M, et al. Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol 2011;25:1388-98
70. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-60
71. Mnie-Filali O, Faure C, Lambás-Señas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275-88
72. Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011;11:101
73. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognition function in early psychosis: a randomised, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061-71
74. Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2011;37:1209-17
75. Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010;128:419-32
76. Snigdha S, Idris N, Grayson B, et al. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 2011;214:843-53
77. Tait DS, Marston HM, Shahid M, et al. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology (Berl) 2009;202:295-306
78. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set-shifting in the rat. J Neurosci 2000;20:4320-4
79. Pantelis C, Barber FZ, Barnes TRE, et al. Comparison of set shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 1999;37:251-70
80. Saleem MM, Harte MK, Marshall KM, et al. Investigation into cognitive function in first episode psychosis patients. Schizophr Res 2010;117:215
81. Paz RD, Tardito S, Atzori M, et al. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18:773-86
82. Elsworth JD, Groman SM, Jentsch JD, et al. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 2012;62:1442-52
83. McLean SL, Neill JC, Idris NF, et al. Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 2010;214:240-7
84. Snigdha S, Neill JC. Improvement of phencyclidine induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 2008;191:26-31
85. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opinion Pharmacol 2011;11:59-67
86. Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist with pro cognitive potential. Int J Neuropsychopharmacol 2010;13:1021-33
87. Idris NF, Neill JC, Grayson B, et al. Sertindole improves sub-chronic PCPinduced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms. Psychopharmacology (Berl) 2010;208:23-36
88. McLean SL, Idris NF, Woolley ML, et al. D1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 2009;19:440-50
89. Akimova E, Lanzenberger R, Kasper S. The serotonin1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-35
90. Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009;88:17-31
91. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
92. Shelton RC, Tollefson GD, Tohen M, et al. Novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
93. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995;374:542-6
94. Stahl SM. Selective histamine H1 antagonism: Novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;13:1027-38